Christina Smolke, Antheia CEO

Say good­bye to plants: Syn­bio play­er An­theia earns new back­ers in quest to re­design flo­ra-de­rived med­i­cine man­u­fac­tur­ing

The age of syn­thet­ic bi­ol­o­gy is of­fi­cial­ly up­on us with su­per-uni­corns like Gink­go Bioworks chang­ing the game in terms of how in­vestors view those cell en­gi­neer­ing plat­forms. Now, a Cal­i­for­nia com­pa­ny look­ing to do away with frag­ile flo­ra sup­ply chains in drug de­vel­op­ment has earned a new round of in­vest­ment to chase its goal.

Syn­bio play­er An­theia raised a $73 mil­lion Se­ries B round it will use to ad­vance its pipeline of com­pounds de­rived from a plant-al­ter­na­tive man­u­fac­tur­ing process us­ing whole yeast cell en­gi­neer­ing, the com­pa­ny said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.